Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12-Reference-Cited by-同舟云学术

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Published:2015-02 Issue:2 Volume:26 Page:313-320
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gnant M.,Mlineritsch B.,Stoeger H.,Luschin-Ebengreuth G.,Knauer M.,Moik M.,Jakesz R.,Seifert M.,Taucher S.,Bjelic-Radisic V.,Balic M.,Eidtmann H.,Eiermann W.,Steger G.,Kwasny W.,Dubsky P.,Selim U.,Fitzal F.,Hochreiner G.,Wette V.,Sevelda P.,Ploner F.,Bartsch R.,Fesl C.,Greil R.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/2/313/16697980/mdu544.pdf

Reference31 articles.

1. St. Gallen 2013: brief preliminary summary of the consensus discussion;Harbeck;Breast Care (Basel),2013

2. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809;Shapiro;Eur J Cancer,2011

3. Bone turnover across the menopause transition: the role of gonadal inhibins;Nicks;Ann N Y Acad Sci,2010

4. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF);Fogelman;Osteoporos Int,2003

5. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer;Hillner;J Clin Oncol,2003

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone complications of cancer treatment;Cancer Treatment Reviews;2024-11

2. Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes;Cancer Treatment Reviews;2024-09

3. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer;Breast Cancer Research and Treatment;2024-07-31

4. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies;European Journal of Endocrinology;2024-07-26

5. Indian Society of Medical and Paediatric Oncology (ISMPO)—Breast Cancer in Young Guidelines;Indian Journal of Medical and Paediatric Oncology;2024-07-22